Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

31.89 -1.14 (-3.45%)
Streaming Delayed Price Updated: 1:54 PM EST, Feb 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
BioCryst Pharmaceuticals Stock Shows Rising Relative Strength ↗
On Monday, BioCryst Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 90 to 93. 
Via Investor's Business Daily
News headline image
Pacira Pharmaceuticals Stock Shows Rising Relative Strength ↗
On Friday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 69 to 73. 
Via Investor's Business Daily
News headline image
Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment ↗
 
Via Benzinga
News headline image
Pain Therapeutics Stock Shows Rising Price Performance With Jump To 97 RS Rating ↗
Pain Therapeutics sees its Relative Strength Rating enter the elite 90-plus level. 
Via Investor's Business Daily
News headline image
Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90 ↗
Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99. 
Via Investor's Business Daily
News headline image
Sage Therapeutics Stock Scores Relative Strength Rating Upgrade ↗
On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91. 
Via Investor's Business Daily
News headline image
HC Wainwright Is Bullish On This Multiple Myeloma Focused Stock ↗
 
Via Benzinga
News headline image
Where Genmab Stands With Analysts ↗
  Genmab (NASDAQ:GMAB) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Genmab, BioNTech Join Forces For Cancer Immunotherapy Candidates ↗
 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Stock Sees Relative Strength Rating Rise To 98 ↗
Amylyx Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating improve to 98, up from 83 the day before. 
Via Investor's Business Daily
News headline image
Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating ↗
Agios Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an increase from 65 to 93. 
Via Investor's Business Daily
News headline image
Legend Biotech Stock Joins Elite Club Of Stocks With RS Ratings Over 90 ↗
On Thursday, Legend Biotech stock had its Relative Strength (RS) Rating upgraded to 91, up from 87 a day earlier. 
Via Investor's Business Daily
News headline image
Golden Cross Appears Before Genmab Investors ↗
If history is any guide, there may be good fortune ahead for shares of Genmab (NASDAQ:GMAB). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the... 
Via Benzinga
News headline image
Intercept Pharmaceutical Stock Shows Market Leadership; Earns 92 RS Rating ↗
On Tuesday, Intercept Pharmaceutical stock had its Relative Strength Rating upgraded to 92, up from 89 a day earlier. 
Via Investor's Business Daily
News headline image
Relay Therapeutics Stock Shows Market Leadership With Jump To 94 RS Rating ↗
Relay Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 84 to 94. 
Via Investor's Business Daily
News headline image
Where Genmab Stands With Analysts ↗
Analysts have provided the following ratings for Genmab (NASDAQ:GMAB) within the last quarter: 
Via Benzinga
News headline image
AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial ↗
 
Via Benzinga
News headline image
Kymera Therapeutics Stock Scores Rising Relative Price Strength ↗
Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength Rating upgradedjulie mak to 94. 
Via Investor's Business Daily
News headline image
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
From Genmab A/S
Via Business Wire
News headline image
AbbVie To Submit European Application For Epcoritamab In Lymphoma Setting Later In 2022 ↗
 
Via Benzinga
News headline image
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
News headline image
Is AbbVie Stock A Buy As Humira Biosimilar Rivals Loom? ↗
Is AbbVie stock a buy today with its biggest medicine, Humira, soon to face biosimilar rivals in the U.S.? Is AbbVie stock a buy today 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium
From Genmab
Via Business Wire
News headline image
Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
From Seagen Inc.
Via Business Wire
News headline image
Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
From Genmab A/S
Via Business Wire
News headline image
Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Genmab
Via Business Wire
News headline image
Johnson & Johnson Stock: A Rare Bright Spot in the Market ↗
JNJ stock is up on the year thanks in part to its steadily rising dividend, which investors covet during the current market volatility. 
Via InvestorPlace
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.